Crinetics Pharmaceuticals Inc - Company Profile
Powered by 
All the sales intelligence you need on Crinetics Pharmaceuticals Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Crinetics Pharmaceuticals Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Crinetics Pharmaceuticals Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Crinetics Pharmaceuticals Inc (Crinetics Pharmaceuticals) is a pharmaceutical company that focuses on developing therapies for endocrine diseases. Its pipeline products include paltusotine an oral somatostatin receptor type 2 (SST2) agonist that treats acromegaly and carcinoid syndrome; and atumelnant (CRN04894), an ACTH agonist that targets Cushing's disease and congenital adrenal hyperplasia (CAH); PTH antagonist, SST3 agonist, SST5 agonist and TSH antagonist for hyperparathyroidism, polycystic kidney disease hyperinsulinism and graves’ disease; oral GLP-1 nonpeptide and oral GIP nonpeptide target diabetes and obesity. The company operates in the US, the Switzerland, and Australia. Crinetics Pharmaceuticals is headquartered in San Diego, California, the US.
Headquarters
United States of America
Address
6055 Lusk Boulevard, San Diego, California, 92121
Website
www.crinetics.com
Telephone
1 858 4506464
No of Employees
594
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
CRNX (NASD)
Revenue (2024)
$7.7M
640.7%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-55.9%
(2024 vs 2023)
Market Cap*
$3.9B
Net Profit Margin (2024)
XYZ
79.0%
(2024 vs 2023)
* As of and is in US$
Crinetics Pharmaceuticals Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| Paltusotine (SST2 Agonist): |
| Acromegaly |
| XYZ |
| XYZ |
| XYZ |
Competitor Comparison
| Key Parameters | Crinetics Pharmaceuticals Inc | Pfizer Inc | AstraZeneca Plc | Novartis AG | Chiesi Farmaceutici SpA |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United Kingdom | Switzerland | Italy |
| City | San Diego | New York City | Cambridge | Basel | Parma |
| State/Province | California | New York | Cambridgeshire | Basel-Stadt | Emilia-Romagna |
| No. of Employees | 594 | 75,000 | 96,100 | 75,267 | 7,686 |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Wendell Wierenga, Ph.D. | Chairman | Executive Board | 2015 | - |
| R. Scott Struthers, Ph.D. | Chief Executive Officer; President; Director | Executive Board | - | - |
| Tobin Schilke | Chief Financial Officer | Senior Management | - | - |
| Jeff Knight | Chief Operating Officer | Senior Management | 2021 | 52 |
| Garlan Adams | Chief Legal Officer | Senior Management | 2021 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer